Skip to main content
Autobound logo
Bristol Myers Squibb10-Q: Product launch

BMY receives multiple major drug approvals in Q2 2026 for Opdivo, Sotyktu, and Breyanzi.

Read at SEC EDGAR

What happened

The company must rapidly scale commercialization efforts, including marketing, sales force enablement, and patient support programs, to capitalize on these new indications and drive revenue growth.

Source

SEC EDGARJul 30, 2026

Quarterly report (Form 10-Q)

Bristol Myers Squibb 10-Q

Filing excerpt

The following is a summary of the significant approvals received in 2026 as of July 30, 2026:

sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htmRead the full source

Other signals in this filing (7)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Jul 30, 2026

More from Bristol Myers Squibb

Company page →

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
14272
Accession number
0000014272-26-000020
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Regions named

  • United States
  • EU
  • Japan

Extraction

Confidence
High
Relevance
90%
Sentiment
Positive
Detected
Aug 4, 2026
signal_type
sec-10q
signal_subtype
productLaunch

Use this data

Get every 10-Q signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/b57ffd1a-a776-4cfc-a0d4-0b4f87a488f9 returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "b57ffd1a-a776-4cfc-a0d4-0b4f87a488f9",
  "signal_type": "sec-10q",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-08-04T07:05:34.637+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "detail": "A string of recent approvals from the FDA, EC, and Japan's MHLW for key growth products creates an immediate need for go-to-market investment. The company must rapidly scale commercialization efforts, including marketing, sales force enablement, and patient support programs, to capitalize on these new indications and drive revenue growth.",
    "metrics": {
      "timeframe": "current_quarter"
    },
    "summary": "BMY receives multiple major drug approvals in Q2 2026 for Opdivo, Sotyktu, and Breyanzi.",
    "excerpts": "The following is a summary of the significant approvals received in 2026 as of July 30, 2026:",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/14272/000001427226000020/bmy-20260630.htm",
    "filing_date": "2026-07-30",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "regions_mentioned": [
      "United States",
      "EU",
      "Japan"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.